Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qol Holdings Co., Ltd. (3034.T)
Tokyo, JP
Headquartered in Tokyo, Japan, Qol Holdings Co., Ltd., established in 1992, operates a diverse portfolio of businesses, primarily focusing on dispensing pharmacies and business process outsourcing (BPO) within the healthcare sector. The company establishes its dispensing pharmacies through tailored, trust-based relationships with individual medical institutions. Beyond its pharmacy operations, Qol Holdings provides extensive BPO services, including conducting sales and marketing research for pharmaceutical companies. It also specializes in dispatching temporary staff across various medical professions, such as pharmacists, nurses, registered sellers, and dietitians. Additionally, the company offers comprehensive support for clinical trials involving both pharmaceuticals and food products. This support encompasses a broad spectrum of services, from assisting with trial execution planning and monitoring to providing secretariat support, statistical analysis, and facilitating the presentation of conference papers, often through the dispatch of skilled managers and technicians. The company further extends its offerings to include publishing-related services. Originally named Qol Co., Ltd., the company adopted its current name, Qol Holdings Co., Ltd., in October 2018.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.26% | +9.44% | +2.23% | +0.52% | -11.86% | -7.63% | +1.69% | +32.76% | +30.07% | +20.09% | +570.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+10.2% ★ Q1'26: +13.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+43.0% ★ Q1'26: +66.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+5.3% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+5.1% Q1'26: +7.2% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+11.7% ★ Q1'26: +18.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.3% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.53× Q1'26: 1.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
131.50B
est: 138.00B (-4.7%)
|
145.52B
est: 145.50B (+0.0%)
|
144.78B
est: 147.93B (-2.1%)
|
165.41B
est: 167.45B (-1.2%)
|
161.83B
est: 162.65B (-0.5%)
|
166.20B
est: 167.35B (-0.7%)
|
170.04B
est: 170.30B (-0.2%)
|
180.05B
est: 181.00B (-0.5%)
|
263.97B
est: 271.00B (-2.6%)
|
292.00B
292.00B – 292.00B
+7.7% YoY
|
311.00B
311.00B – 311.00B
+6.5% YoY
|
316.00B
316.00B – 316.00B
+1.6% YoY
|
340.00B
340.00B – 340.00B
+7.6% YoY
|
| EBITDA |
10.82B
est: 11.18B (-3.3%)
|
12.48B
est: 11.79B (+5.8%)
|
11.38B
est: 11.99B (-5.1%)
|
12.42B
est: 13.57B (-8.5%)
|
11.67B
est: 13.18B (-11.4%)
|
14.52B
est: 13.56B (+7.1%)
|
14.56B
est: 13.80B (+5.5%)
|
14.21B
est: 14.67B (-3.1%)
|
21.42B
est: 22.63B (-5.3%)
|
24.39B
24.39B – 24.39B
+7.7% YoY
|
25.97B
25.97B – 25.97B
+6.5% YoY
|
26.39B
26.39B – 26.39B
+1.6% YoY
|
28.39B
28.39B – 28.39B
+7.6% YoY
|
| EBIT |
7.29B
est: 7.13B (+2.2%)
|
8.51B
est: 7.52B (+13.2%)
|
7.26B
est: 7.64B (-5.0%)
|
7.80B
est: 8.65B (-9.8%)
|
7.01B
est: 8.41B (-16.6%)
|
9.79B
est: 8.65B (+13.2%)
|
9.67B
est: 8.80B (+9.9%)
|
8.97B
est: 9.35B (-4.1%)
|
13.06B
est: 14.41B (-9.3%)
|
15.53B
15.53B – 15.53B
+7.7% YoY
|
16.54B
16.54B – 16.54B
+6.5% YoY
|
16.80B
16.80B – 16.80B
+1.6% YoY
|
18.08B
18.08B – 18.08B
+7.6% YoY
|
| Net Income |
4.35B
|
4.99B
est: 4.78B (+4.2%)
|
3.91B
est: 4.28B (-8.8%)
|
4.07B
est: 3.98B (+2.3%)
|
3.37B
est: 3.32B (+1.4%)
|
5.49B
est: 5.44B (+0.9%)
|
5.66B
est: 5.35B (+5.7%)
|
4.88B
est: 5.32B (-8.3%)
|
5.16B
est: 5.00B (+3.2%)
|
6.30B
6.30B – 6.30B
+25.8% YoY
|
7.19B
7.19B – 7.19B
+14.3% YoY
|
7.49B
7.49B – 7.49B
+4.2% YoY
|
10.10B
10.10B – 10.10B
+34.8% YoY
|
| SGA |
8.06B
est: 9.24B (-12.8%)
|
8.22B
est: 9.75B (-15.7%)
|
8.41B
est: 9.91B (-15.1%)
|
10.29B
est: 11.22B (-8.2%)
|
10.65B
est: 10.90B (-2.3%)
|
10.14B
est: 11.21B (-9.6%)
|
10.81B
est: 11.41B (-5.3%)
|
11.53B
est: 12.13B (-4.9%)
|
21.26B
est: 18.66B (+13.9%)
|
20.11B
20.11B – 20.11B
+7.7% YoY
|
21.42B
21.42B – 21.42B
+6.5% YoY
|
21.76B
21.76B – 21.76B
+1.6% YoY
|
23.42B
23.42B – 23.42B
+7.6% YoY
|
| EPS |
128.35
|
130.19
est: 127.80 (+1.9%)
|
101.70
est: 114.47 (-11.2%)
|
107.22
est: 106.20 (+1.0%)
|
89.53
est: 88.68 (+1.0%)
|
149.49
est: 145.30 (+2.9%)
|
152.95
est: 142.90 (+7.0%)
|
131.10
est: 142.10 (-7.7%)
|
137.95
est: 133.30 (+3.5%)
|
167.70
167.70 – 167.70
+25.8% YoY
|
191.60
191.60 – 191.60
+14.3% YoY
|
199.60
199.60 – 199.60
+4.2% YoY
|
269.00
269.00 – 269.00
+34.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.04% | 134.4K | 0.58% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.03% | 283.7K | 0.40% |
| 3 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.02% | 78.3K | 0.31% |
| 4 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 177.1K | 0.40% |
| 5 | Dimensional - International Vector Equity ETF DXIV | 0.02% | 30.2K | 0.53% |
| 6 | WisdomTree International Equity Fund DWM | 0.01% | 88.2K | 0.48% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.01% | 726.4K | 0.39% |
| 8 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 437.9K | 0.06% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 873.3K | 0.06% |
| 10 | Dimensional International Sustainability Core 1 ETF DFSI | 0.01% | 66.9K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Kawaguchi | Chief of Gen Afrs & Disaster Countermeasures HQ, GM of Gen & Legal Afrs Dept and Director | — | — |
| Kiyonobu Fukumitsu | Representative, Chief of Business Management Headquarters & Executive Director | — | male |
| Shinobu Karasawa | Chief of Pharmacy Business Headquarters & Executive Director | — | female |
| Takashi Nakamura | President & Representative Director | — | male |
| Takayoshi Ishii | Chief of Corporate Strategy Headquarters and Senior Executive & Representative Director | — | male |
| Yuji Suzuki | Deputy Chief of Pharmacy Business Headquarters & Director | — | — |
| Yutaka Togashi | Chief of Human Resources & Education Headquarters and Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3034.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
